CR20180246A - Prevención, tratamiento y reversión de enfermedad usando cantidades terapéuticamente efectivas de ácidos grasos activados - Google Patents
Prevención, tratamiento y reversión de enfermedad usando cantidades terapéuticamente efectivas de ácidos grasos activadosInfo
- Publication number
- CR20180246A CR20180246A CR20180246A CR20180246A CR20180246A CR 20180246 A CR20180246 A CR 20180246A CR 20180246 A CR20180246 A CR 20180246A CR 20180246 A CR20180246 A CR 20180246A CR 20180246 A CR20180246 A CR 20180246A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fatty acids
- reversion
- disease
- prevention
- treatment
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 5
- 229930195729 fatty acid Natural products 0.000 title abstract 5
- 239000000194 fatty acid Substances 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 150000004665 fatty acids Chemical class 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- -1 keto fatty acids Chemical class 0.000 abstract 2
- WRADPCFZZWXOTI-BMRADRMJSA-N (9E)-10-nitrooctadecenoic acid Chemical compound CCCCCCCC\C([N+]([O-])=O)=C/CCCCCCCC(O)=O WRADPCFZZWXOTI-BMRADRMJSA-N 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 abstract 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236702P | 2015-10-02 | 2015-10-02 | |
| PCT/US2016/055206 WO2017059451A1 (en) | 2015-10-02 | 2016-10-03 | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180246A true CR20180246A (es) | 2018-11-22 |
Family
ID=58428002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180246A CR20180246A (es) | 2015-10-02 | 2016-10-03 | Prevención, tratamiento y reversión de enfermedad usando cantidades terapéuticamente efectivas de ácidos grasos activados |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10537541B2 (https=) |
| EP (1) | EP3355879A4 (https=) |
| JP (2) | JP2018529779A (https=) |
| KR (1) | KR20180098222A (https=) |
| CN (2) | CN108430466A (https=) |
| AU (2) | AU2016331314A1 (https=) |
| BR (1) | BR112018006687A2 (https=) |
| CA (1) | CA3000842A1 (https=) |
| CL (1) | CL2018000835A1 (https=) |
| CO (1) | CO2018004576A2 (https=) |
| CR (1) | CR20180246A (https=) |
| EA (1) | EA201890859A1 (https=) |
| HK (1) | HK1259031A1 (https=) |
| IL (2) | IL258476B2 (https=) |
| MX (1) | MX2018004043A (https=) |
| SG (1) | SG10201913953UA (https=) |
| WO (1) | WO2017059451A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011519373A (ja) * | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | ビニル置換脂肪酸 |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| WO2017059451A1 (en) * | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| CA3110680A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| CN111229117B (zh) * | 2018-11-29 | 2022-01-04 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
| CN111229120B (zh) * | 2018-11-29 | 2022-01-07 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
| FR3092968B1 (fr) * | 2019-02-22 | 2021-05-21 | Microphyt | Complement alimentaire |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| WO2021242758A1 (en) * | 2020-05-26 | 2021-12-02 | Imara Inc. | Improved nitro-fatty acid oral dose regimens |
| WO2023014748A1 (en) * | 2021-08-03 | 2023-02-09 | Imara Inc. | Nitrated fatty acids for the treatment of sickle cell disorders |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB587992A (en) | 1944-12-11 | 1947-05-12 | Charles William Scaife | Improvements in and relating to the production of organic nitrogen compounds |
| US3578687A (en) | 1968-01-30 | 1971-05-11 | Texaco Inc | Process for producing 4-nitroalkanoic acids |
| US3819561A (en) | 1970-10-23 | 1974-06-25 | Aerojet General Co | Wetting agents for non-aqueous dispersions |
| JPS5313608B2 (https=) | 1972-06-16 | 1978-05-11 | ||
| JPS5318013B2 (https=) | 1973-03-19 | 1978-06-13 | ||
| US4599430A (en) | 1981-12-21 | 1986-07-08 | The Standard Oil Company | Nitrogenation of hydrocarbons, including the production of maleimide |
| JPS62132804A (ja) | 1985-12-05 | 1987-06-16 | Aguro Kanesho Kk | 植物生長調節剤 |
| US5412137A (en) | 1993-06-07 | 1995-05-02 | Sandoz Ltd. | Process for preparing phosphinyloxy propanaminium inner salt derivatives |
| JPH10507179A (ja) | 1994-10-13 | 1998-07-14 | ペプチド テクノロジー リミテッド | 修飾ポリ不飽和脂肪酸 |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
| GB9618420D0 (en) | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
| US6531150B1 (en) | 1997-10-30 | 2003-03-11 | Morishita Jintan Co., Ltd. | Encapsulated unsaturated fatty acid substance and method for producing the same |
| WO2000009075A2 (en) | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
| AU5319499A (en) | 1999-07-22 | 2001-02-13 | Ivan L. Cameron | Fatty acids to minimize cancer therapy side effects |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
| US6346231B1 (en) | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
| US20010037598A1 (en) | 1999-12-14 | 2001-11-08 | Suppes Galen J. | Process for producing cetane improvers from triglycerides |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
| AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
| AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
| EP1294658B1 (en) | 2000-06-28 | 2005-03-02 | ZAMBON GROUP S.p.A. | Process for the preparation of nitroalkenes |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| JP5026655B2 (ja) | 2001-04-18 | 2012-09-12 | プロメティック、バイオサイエンシーズ、インコーポレーテッド | 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体 |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| EP1407767A4 (en) | 2001-06-18 | 2007-01-24 | Yamada Sachiko | AGONIST MEDICINAL PREPARATIONS PPAR $ G (G) |
| EP1418876A4 (en) | 2001-08-17 | 2007-07-11 | Univ Pittsburgh | ADMINISTRATION OF OSTRADIOL METABOLITES FOR THE TREATMENT OR PREVENTION OF ADIPOSITAS, METABOLIC SYNDROME, DIABETES AND VASCULAR AND KIDNEY DISEASES |
| GB0123961D0 (en) | 2001-10-05 | 2001-11-28 | Astrazeneca Ab | Process and intermediates |
| US20030166716A1 (en) | 2001-11-06 | 2003-09-04 | Serhan Charles N. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
| CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
| EP2384750A1 (en) | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| WO2005016864A1 (en) | 2003-07-29 | 2005-02-24 | The Arizona Disease Control Research Commission | Conjugated nitro alkene anticancer agents based on isoprenoid metabolism |
| US20050136103A1 (en) | 2003-09-17 | 2005-06-23 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| US20090215895A1 (en) | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| US7776916B2 (en) * | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
| RU2527893C2 (ru) | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| EP1772149A1 (en) | 2004-07-27 | 2007-04-11 | Kowa Company. Ltd. | Drug for prevention or treatment of diabetes |
| BRPI0516803A (pt) | 2004-11-19 | 2008-09-23 | Martek Biosciences Corp | oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos |
| WO2006086727A2 (en) | 2005-02-09 | 2006-08-17 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
| US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| WO2008008767A2 (en) | 2006-07-14 | 2008-01-17 | Cedars-Sinai Medical Center | Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer |
| MX2009000657A (es) | 2006-07-19 | 2009-05-28 | Resolvyx Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de mucositis. |
| WO2008103753A2 (en) | 2007-02-20 | 2008-08-28 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
| WO2009017802A1 (en) | 2007-08-01 | 2009-02-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nitro-fattyacid modulation of type ii diabetes |
| CA2699483A1 (en) | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
| WO2009129495A1 (en) | 2008-04-18 | 2009-10-22 | The University Of Utah Research Foundation | Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
| JP2011519373A (ja) | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | ビニル置換脂肪酸 |
| WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
| EP2299997A4 (en) | 2008-06-19 | 2012-01-11 | Univ Utah Res Found | USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US8933255B2 (en) * | 2008-12-31 | 2015-01-13 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
| US8937194B2 (en) | 2008-12-31 | 2015-01-20 | Nitromega Corp. | Topical compositions containing nitro fatty acids |
| US20100286271A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Nitro-alkyl Compound Compositions |
| US20100286272A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications |
| US20100286257A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging |
| JP2013500275A (ja) | 2009-07-29 | 2013-01-07 | フェノメノーム ディスカバリーズ インク | ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用 |
| EP3045167A1 (en) | 2009-07-31 | 2016-07-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Keto fatty acids as anti-inflammatory agents |
| EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
| CA2777455A1 (en) | 2009-11-09 | 2011-05-12 | Novadex Pharmaceuticals Ab | Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| KR20130054249A (ko) * | 2010-03-15 | 2013-05-24 | 울리히 디에츠 | 공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도 |
| EP2568826A4 (en) | 2010-05-13 | 2014-03-26 | Nitromega Corp | NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE |
| US20110319325A1 (en) | 2010-06-28 | 2011-12-29 | Complexa, Inc. | Multi-component pharmaceuticals for treating diabetes |
| WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
| US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
| DE102012008730A1 (de) | 2011-12-02 | 2013-06-06 | Dr. Budz GmbH | Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung |
| WO2013116753A1 (en) | 2012-02-03 | 2013-08-08 | University Of Pittsburgh-Of The Commonwelth System Of Higher Education | Fatty acids as anti-inflammatory agents |
| US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
| CN105339006A (zh) | 2013-05-10 | 2016-02-17 | 尼特罗米加公司 | 含有脂肪酸和亚硝酸盐的营养或膳食补充剂 |
| US20150051283A1 (en) | 2013-06-14 | 2015-02-19 | Complexa, Inc. | Composition and method for inhibition of pkng from mycobacterium tuberculosis |
| WO2015073527A1 (en) | 2013-11-12 | 2015-05-21 | Complexa, Inc. | Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions |
| WO2016161285A1 (en) * | 2015-04-02 | 2016-10-06 | Aobiome Llc | Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria |
| WO2017059451A1 (en) * | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
-
2016
- 2016-10-03 WO PCT/US2016/055206 patent/WO2017059451A1/en not_active Ceased
- 2016-10-03 IL IL258476A patent/IL258476B2/en unknown
- 2016-10-03 HK HK19101519.9A patent/HK1259031A1/zh unknown
- 2016-10-03 CR CR20180246A patent/CR20180246A/es unknown
- 2016-10-03 IL IL297844A patent/IL297844A/en unknown
- 2016-10-03 JP JP2018536704A patent/JP2018529779A/ja not_active Withdrawn
- 2016-10-03 CN CN201680070797.XA patent/CN108430466A/zh active Pending
- 2016-10-03 AU AU2016331314A patent/AU2016331314A1/en not_active Abandoned
- 2016-10-03 CA CA3000842A patent/CA3000842A1/en not_active Abandoned
- 2016-10-03 MX MX2018004043A patent/MX2018004043A/es unknown
- 2016-10-03 BR BR112018006687A patent/BR112018006687A2/pt not_active Application Discontinuation
- 2016-10-03 SG SG10201913953UA patent/SG10201913953UA/en unknown
- 2016-10-03 KR KR1020187012337A patent/KR20180098222A/ko not_active Ceased
- 2016-10-03 CN CN202110744035.6A patent/CN113440506A/zh active Pending
- 2016-10-03 EA EA201890859A patent/EA201890859A1/ru unknown
- 2016-10-03 EP EP16852846.1A patent/EP3355879A4/en not_active Withdrawn
- 2016-10-03 US US15/283,887 patent/US10537541B2/en not_active Expired - Fee Related
-
2018
- 2018-03-29 CL CL2018000835A patent/CL2018000835A1/es unknown
- 2018-04-27 CO CONC2018/0004576A patent/CO2018004576A2/es unknown
-
2019
- 2019-10-18 US US16/657,028 patent/US20200046669A1/en not_active Abandoned
-
2021
- 2021-03-19 US US17/207,380 patent/US20220000824A1/en not_active Abandoned
- 2021-07-14 AU AU2021205027A patent/AU2021205027A1/en not_active Abandoned
- 2021-08-27 JP JP2021139287A patent/JP2021183640A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017059451A1 (en) | 2017-04-06 |
| CA3000842A1 (en) | 2017-04-06 |
| IL258476B (en) | 2022-12-01 |
| US10537541B2 (en) | 2020-01-21 |
| US20200046669A1 (en) | 2020-02-13 |
| BR112018006687A2 (pt) | 2018-10-09 |
| CO2018004576A2 (es) | 2018-07-19 |
| EP3355879A4 (en) | 2019-05-22 |
| IL258476A (en) | 2018-06-28 |
| JP2021183640A (ja) | 2021-12-02 |
| US20220000824A1 (en) | 2022-01-06 |
| EP3355879A1 (en) | 2018-08-08 |
| MX2018004043A (es) | 2018-11-09 |
| CN113440506A (zh) | 2021-09-28 |
| KR20180098222A (ko) | 2018-09-03 |
| CL2018000835A1 (es) | 2018-09-14 |
| IL258476B2 (en) | 2023-04-01 |
| HK1259031A1 (zh) | 2019-11-22 |
| AU2021205027A1 (en) | 2021-08-12 |
| AU2016331314A1 (en) | 2018-05-17 |
| EA201890859A1 (ru) | 2018-11-30 |
| US20170095437A1 (en) | 2017-04-06 |
| JP2018529779A (ja) | 2018-10-11 |
| SG10201913953UA (en) | 2020-03-30 |
| IL297844A (en) | 2023-01-01 |
| CN108430466A (zh) | 2018-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20180246A (es) | Prevención, tratamiento y reversión de enfermedad usando cantidades terapéuticamente efectivas de ácidos grasos activados | |
| EA201891248A1 (ru) | Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| EA201792354A1 (ru) | Композиции обетихолевой кислоты и способы применения | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| IL259876B (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
| EP3562514A4 (en) | GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| BR112016026809A2 (pt) | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| PE20180258A1 (es) | Inhibidores de bromodominio | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| EP3294345A4 (en) | TPP1 FORMULATIONS AND METHOD FOR THE TREATMENT OF CLN2 DISEASES | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| UY37236A (es) | Ésteres de oxaborol y sus usos | |
| EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EP3318261A4 (en) | Use of zoledronic acid to prepare drug treating fatty liver disease | |
| EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
| EP3866795A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| KR20180085033A (ko) | 피부 질환 치료용 약학적 제형 및 이의 제조 방법 | |
| EP3569249A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE |